RXi Pharmaceuticals Q1 Loss Narrows - Quick Facts

(RTTNews) - Biotechnology company RXi Pharmaceuticals Corp. (RXII) reported that first quarter net loss attributable to common stockholders narrowed to $3.13 million or $0.13 per share from $4.04 million or $0.32 per share in the prior-year quarter.

Total revenues for the quarter grew to $34,000 from $29,000 in the same quarter last year.

On average, analysts polled by Thomson Reuters expected the company to a loss of $0.10 per share on revenues of 20,000 for the quarter. Analysts' estimates typically exclude special items.

Loss from operations widened to $2.95 million from $2.29 million, and research and development expenses grew to $2.11 million from $1.48 million in the year-ago quarter.